Publicaciones en colaboración con investigadores/as de Hospital de Galdakao - Usansolo (181)

2024

  1. Trends in Targeted Therapy Usage in Inflammatory Bowel Disease: TRENDY Study of ENEIDA

    Pharmaceutics, Vol. 16, Núm. 5

  2. Use of Darvadstrocel (Allogenic Stem Cell Therapy) for Crohn’s Fistulas in Real Clinical Practice: The National Project to Implement Mesenchymal Stem Cell for the Treatment of Perianal Crohn’s Fistula (the PRIME Study)

    Diseases of the Colon and Rectum, Vol. 67, Núm. 7, pp. 960-967

2023

  1. A second update on mapping the human genetic architecture of COVID-19

    Nature

  2. Comparative Effectiveness of Autologous Hematopoietic Stem Cell Transplant vs Fingolimod, Natalizumab, and Ocrelizumab in Highly Active Relapsing-Remitting Multiple Sclerosis

    JAMA Neurology, Vol. 80, Núm. 7, pp. 702-713

  3. Comparative effectiveness in multiple sclerosis: A methodological comparison

    Multiple Sclerosis Journal, Vol. 29, Núm. 3, pp. 326-332

  4. Correction to: Five-year follow-up mortality prognostic index for colorectal patients (International Journal of Colorectal Disease, (2023), 38, 1, (64), 10.1007/s00384-023-04358-0)

    International Journal of Colorectal Disease

  5. Detecting disability using self-reported and clinical assessments in early-stage relapsing-remitting multiple sclerosis: Looking for a complementary approach

    Multiple Sclerosis Journal - Experimental, Translational and Clinical, Vol. 9, Núm. 2

  6. Development and Validation of a Prediction Model and Score for Transthyretin Cardiac Amyloidosis Diagnosis: T-Amylo

    JACC: Cardiovascular Imaging, Vol. 16, Núm. 12, pp. 1567-1580

  7. Disability accrual in primary and secondary progressive multiple sclerosis

    Journal of Neurology, Neurosurgery and Psychiatry, Vol. 94, Núm. 9, pp. 707-717

  8. Early non-disabling relapses are important predictors of disability accumulation in people with relapsing-remitting multiple sclerosis

    Multiple sclerosis (Houndmills, Basingstoke, England), Vol. 29, Núm. 7, pp. 875-883

  9. Effectiveness of multiple disease-modifying therapies in relapsing-remitting multiple sclerosis: causal inference to emulate a multiarm randomised trial

    Journal of neurology, neurosurgery, and psychiatry, Vol. 94, Núm. 12, pp. 1004-1011

  10. Erratum to: Mapping the human genetic architecture of COVID-19 (Nature, (2021), 600, 7889, (472-477), 10.1038/s41586-021-03767-x)

    Nature

  11. Factors associated with the hospital at home workload: A Delphi consensus study

    Journal of Healthcare Quality Research, Vol. 38, Núm. 4, pp. 233-244

  12. Feasibility of a screening algorithm for chronic thromboembolic pulmonary hypertension: The OSIRIS study

    Thrombosis Research, Vol. 228, pp. 1-9

  13. First-Line Versus Second-Line Use of Reslizumab in Severe Uncontrolled Asthma

    Journal of Investigational Allergology and Clinical Immunology

  14. Five-year follow-up mortality prognostic index for colorectal patients

    International Journal of Colorectal Disease, Vol. 38, Núm. 1

  15. Hopelessness in Patients with Early-Stage Relapsing-Remitting Multiple Sclerosis

    Patient Preference and Adherence, Vol. 17, pp. 1431-1439

  16. Pneumococcal Serotypes Associated with Community-Acquired Pneumonia Hospitalizations in Adults in Spain, 2016–2020: The CAPA Study

    Microorganisms, Vol. 11, Núm. 11

  17. Quality Indicators and Outcomes in a Prospective Cohort of Colorectal Cancer Patients

    Journal of Gastrointestinal Cancer, Vol. 54, Núm. 1, pp. 20-26

  18. The risk of secondary progressive multiple sclerosis is geographically determined but modifiable

    Brain : a journal of neurology, Vol. 146, Núm. 11, pp. 4633-4644